DENVER--(BUSINESS WIRE)--PRESS RELEASE--MedPharm, a medical cannabis grow, R&D laboratory and compounding facility, has announced that it has been awarded the first cannabis research license by the state of Colorado. To get the license, the state looked at the applicant’s capabilities to successfully develop and conduct research.
The cannabis research license was created by the state to allow cannabis-related operators and researchers to study the plant and better understand what it offers. The application for the license included outlining research objectives and creating areas where medical research cannabis is grown specifically for research purposes.
“We have a strong research team of some of the best and brightest in the industry, and this cannabis research license will really help us in our quest to be a world leader in dosage formulation and product development,” Albert Gutierrez, CEO of MedPharm, says. “We are eager to look at what benefits the plant might offer for improving the human condition.”
Dr. Tyrell Towle, the director of chemistry for MedPharm with a PhD in medicinal and natural products chemistry, says that the cannabis research license will enable MedPharm to provide their high-quality dosage forms directly to study patients. “It will also allow us to perform Randomized Controlled Trials (RCTs) because we can supply placebos as well, which wasn’t previously allowed for,” he says. “We are now in a better position than any cannabis company to take on research partnerships and we welcome those who are interested in such partnerships.”
MedPharm currently makes three brands: Aliviar, a medically-focused brand that produces pharmaceutical grade dosage forms (www.aliviaralleviates.com); Become products for a mellow, balanced or elevated feeling (www.becomelifestyle.com); and Batch, an oil concentrate with higher percentages of THC for the cannabis connoisseur (www.batchextracts.com). “Our recent review of our strains shows a very rare and unique cannabinoid that we originally dismissed as interference. We were able to identify the cannabinoid and see its molecular structure, which is exciting,” Towle says.
